Last reviewed · How we verify
OGX-427 1000 mg
OGX-427 1000 mg is a Small molecule drug developed by Achieve Life Sciences. It is currently in Phase 2 development. Also known as: apatorsen.
At a glance
| Generic name | OGX-427 1000 mg |
|---|---|
| Also known as | apatorsen |
| Sponsor | Achieve Life Sciences |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone (PHASE2)
- OGX-427 in Castration Resistant Prostate Cancer Patients (PHASE2)
- A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OGX-427 1000 mg CI brief — competitive landscape report
- OGX-427 1000 mg updates RSS · CI watch RSS
- Achieve Life Sciences portfolio CI
Frequently asked questions about OGX-427 1000 mg
What is OGX-427 1000 mg?
OGX-427 1000 mg is a Small molecule drug developed by Achieve Life Sciences.
Who makes OGX-427 1000 mg?
OGX-427 1000 mg is developed by Achieve Life Sciences (see full Achieve Life Sciences pipeline at /company/achieve-life-sciences).
Is OGX-427 1000 mg also known as anything else?
OGX-427 1000 mg is also known as apatorsen.
What development phase is OGX-427 1000 mg in?
OGX-427 1000 mg is in Phase 2.
Related
- Manufacturer: Achieve Life Sciences — full pipeline
- Also known as: apatorsen
- Compare: OGX-427 1000 mg vs similar drugs
- Pricing: OGX-427 1000 mg cost, discount & access